MedTrace Logo

Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury

NCT03070353 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-03-03

No results posted yet for this study

Summary

A pilot study of Dextran-40 infusion in patients with decompensated cirrhosis presenting with AKI

Conditions

  • Cirrhosis, Liver
  • AKI

Interventions

DRUG

Dextran 40

Dextran-40 infusion with the dose of 1 g/kg/day (10 ml/kg/day) for 2 days.

Sponsors & Collaborators

  • Ramathibodi Hospital

    lead OTHER

Principal Investigators

  • Abhasnee Sobhonslidsuk, MD · Ramathibodi Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-01
Primary Completion
2016-06-30
Completion
2016-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03070353 on ClinicalTrials.gov